Donnerstag,
10.11.2022 06:30
von
PR Newswire
| Aufrufe: 95
BD Reports Fourth Quarter and Full Year Fiscal 2022 Financial Results
Ein Labormiskroskop (Symbolbild).
pixabay.com
PR Newswire
FRANKLIN LAKES, N.J., Nov. 10, 2022
Execution of BD 2025 Strategy Driving Consistent Durable Growth
- Q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and increased 2.3% on a currency-neutral basis
- Q4 revenue performance driven by base revenue growth of 4.2% as reported, 8.6% currency-neutral
- Q4 GAAP and adjusted diluted EPS from continuing operations of $0.92 and $2.75, respectively
- FY22 revenue from continuing operations of $18.9 billion decreased 1.4% as reported and increased 0.9% on a currency-neutral basis
- FY22 revenue performance driven by base revenue growth of 6.9% as reported, 9.4% currency-neutral
- FY22 GAAP and adjusted diluted EPS from continuing operations of $5.38 and $11.35, respectively
- Company issues FY23 guidance; announces 51st consecutive year of dividend increases, dividend raised 4.6%
FRANKLIN LAKES, N.J., Nov. 10, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fourth quarter and full year of fiscal 2022, which ended September 30, 2022.
"Fiscal 2022 was another outstanding year with impactful results that confirm the effectiveness of our BD 2025 strategy," said Tom Polen, chairman, CEO and president of BD. "We delivered reliable, consistent performance that reflects our team's unwavering commitment to our purpose and the execution of our growth plan – while navigating the challenging macro environment all companies are facing. Looking forward, our strong performance and momentum increases our confidence to continue to create substantial, sustained value for all stakeholders."
Recent Business Highlights
BD continues to advance its innovation-driven growth strategy, tuck-in M&A, and ESG initiatives.
- Launched BD® Research Cloud in the US. State-of-the-art software solution streamlines research flow cytometry workflow through integrated ecosystem that enables customers to design, run and analyze experiments.
- Launched BD Effivax™. Next-generation glass prefillable syringe sets new standard in performance for vaccines.
- Announced agreement with Biocorp to bring connectivity and traceability to self-administered injectable drug therapies like biologics, addressing an unmet need and furthering BD's commitment to smart, connected care, enabling care to transition to alternate settings and improving chronic disease outcomes.
- Named to Forbes' 2022 list of the World's Best Employers.
Basis of Presentation— Continuing Operations
On April 1, 2022, the Company completed the spin-off of its Diabetes Care business as a separate publicly traded company named Embecta Corp. ("Embecta"). The historical results of the Diabetes Care business that was contributed to Embecta in the spin-off are now accounted for as discontinued operations. Financial information presented in this release reflects BD's results on a continuing operations basis, which excludes Embecta. Prior periods have been recast to conform to this presentation.
Fourth Quarter Fiscal 2022 Operating Results
| | | Three Months Ended September 30, | | Change | | Foreign Currency | ||
| (Millions of dollars, except per share amounts) | | 2022 | | 2021 | | | ||
| Revenues | | $ 4,761 | | $ 4,849 | | (1.8) % | | 2.3 % |
| Base Revenues1 | | $ 4,724 | | $ 4,533 | | 4.2 % | | 8.6 % |
| Base Organic Revenue Growth1 | | | | | | 2.4 % | | 6.8 % |
| Reported Diluted Earnings per Share | | $ 0.92 | | $ 0.46 | | 100.0 % | | 137.0 % |
| Adjusted Diluted Earnings per Share1 | | $ 2.75 | | $ 2.15 | | 27.9 % | | 36.3 % |
| |
| 1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables. Base revenues denotes total revenues less estimated revenues for COVID-19-only diagnostic testing. Base Organic Revenue Growth excludes the contribution from inorganic revenues from acquisitions, which is defined as revenues recognized during the first 12 months post-acquisition. |
Geographic Results
| Revenues (Millions of dollars) | | Three Months Ended September 30, | | Reported Change | | Foreign Currency | ||
| | | 2022 | | 2021 | | | ||
| United States | | $ 2,708 | | $ 2,649 | | 2.2 % | | 2.2 % |
| International | | $ 2,053 | | $ 2,200 | | (6.7) % | | 2.4 % |
| Total Revenues | | $ 4,761 | | $ 4,849 | | (1.8) % | | 2.3 % |
| |
| 1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables. |
Segment Results
| Revenues (Millions of dollars) | | Three Months Ended | | Reported | | Foreign | | Reported | | Foreign Currency | ||
| | | 2022 | | 2021 | | | | | ||||
| BD Medical | | $ 2,377 | | $ 2,246 | | 5.8 % | | 10.2 % | | 5.8 % | | 10.2 % |
| BD Life Sciences | | $ 1,287 | | $ 1,532 | | (15.9) % | | (11.6) % | | 2.9 % | | 8.3 % |
| BD Interventional | | $ 1,097 | | $ 1,071 | | 2.4 % | | 5.7 % | | 2.4 % | | 5.7 % |
| Total Revenues | | $ 4,761 | | $ 4,849 | | (1.8) % | | 2.3 % | | 4.2 % Werbung Mehr Nachrichten zur Becton Dickinson Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | ||
